Related Experiment Video
Updated: Oct 2, 2025
Recurrent Herpetic Stromal Keratitis in Mice, a Model for Studying Human HSK
Published on: December 18, 2012
Human Herpesvirus 6A Is a Risk Factor for Multiple Sclerosis
Wangko Lundström1, Rasmus Gustafsson1
1Center for Molecular Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Abstract:
The role for human herpesvirus (HHV)-6A or HHV-6B in multiple sclerosis (MS) pathogenesis has been controversial. Possibly because the damage of the virus infection may occur before onset of clinical symptoms and because it has been difficult to detect active infection and separate serological responses to HHV-6A or 6B. Recent studies report that in MS patients the serological response against HHV-6A is increased whereas it is decreased against HHV-6B. This effect seems to be even more pronounced in MS patients prior to diagnosis and supports previous studies postulating a predomination for HHV-6A in MS disease and suggests that the infection is important at early stages of the disease. Furthermore, HHV-6A infection interacts with other factors suspected of modulating MS susceptibility and progression such as infection with Epstein-Barr virus (EBV) and Cytomegalovirus (CMV), tobacco smoking, HLA alleles, UV irradiation and vitamin D levels. The multifactorial nature of MS and pathophysiological role for HHV-6A in inflammation and autoimmunity are discussed.
Insights
Human herpesvirus 6A (HHV-6A) may play a role in early multiple sclerosis (MS) development. Research indicates altered HHV-6A and HHV-6B serological responses in MS patients, suggesting HHV-6A
Area of Science:
- Neurovirology
- Immunology
- Epidemiology
Background:
- The role of human herpesvirus (HHV)-6A and HHV-6B in multiple sclerosis (MS) pathogenesis remains debated.
- Challenges in detecting active infections and differentiating serological responses complicate MS-HHV research.
- Previous studies suggest HHV-6A involvement in MS, but definitive evidence is lacking.
Purpose of the Study:
- To investigate the differential serological responses to HHV-6A and HHV-6B in multiple sclerosis (MS) patients.
- To explore the potential role of HHV-6A in the early stages of MS pathogenesis.
- To examine interactions between HHV-6A and other MS risk factors.
Main Methods:
- Analysis of serological responses to HHV-6A and HHV-6B in MS patients.
- Comparison of serological profiles in pre-diagnosis MS patients versus controls.
- Review of existing literature on HHV-6A interactions with MS risk factors.
Main Results:
- MS patients exhibit increased serological response to HHV-6A and decreased response to HHV-6B.
- This differential response is more pronounced in pre-diagnosis MS patients.
- HHV-6A infection interacts with other MS risk factors like EBV, CMV, smoking, and vitamin D levels.
Conclusions:
- Findings support a predominant role for HHV-6A in MS pathogenesis, particularly in early disease stages.
- HHV-6A may contribute to MS through inflammation and autoimmunity.
- The multifactorial nature of MS involves interactions between viral infections and environmental factors.
